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Context: Reports of polytetrafluoroethylene (PTFE) bypass grafting to the infrapopliteal arteries have often used survival
analysis of acceptable quality to describe a wide range of long-term results. In theory, these results may be combined if
variability between series and time intervals is considered.
Objective: Meta-analysis was performed to gain insight into long-term graft patency and foot preservation after PTFE
bypass grafting to infrapopliteal arteries.
Data source: Studies published from 1982 through 2001 were identified from the PubMed database and pertinent
original articles.
Study selection: Three investigators selected 43 studies that used survival analysis, reported 2-year patency rates, and
included at least 15 bypass procedures.
Data extraction and transformation: Based on standard life-tables or survivor curves, an interval success rate was
calculated for each month in each series. The monthly success rates were combined across series, enabling construction of
pooled survivor curves.
Data synthesis: Random-effects meta-analysis yielded 5-year pooled estimates (SE) of 30.5% (7.6%) for primary graft
patency, 39.7% (5.5%) for secondary graft patency, and 55.7% (5.0%) for foot preservation. During the entire follow-up,
pooled estimates were slightly higher for series of PTFE grafts with adjunctive procedures compared with series of PTFE
grafts only.
Sensitivity analysis: A simulation using only unfavorable assumptions showed a decrease of less than 5% at 5 years for all
outcomes, and smaller differences at subgroup meta-analysis. Funnel plots suggested that publication bias was unlikely.
Conclusion: This meta-analysis indicated moderate success for PTFE bypass grafts to infrapopliteal arteries, but the role
of adjunctive procedures at the distal anastomosis remains uncertain. (J Vasc Surg 2003;37:1263-9.)
The great saphenous vein compares favorably with
other materials in bypass grafting to infrapopliteal arteries,
but this vein and other autologous veins also suitable for
bypass grafting may be lacking even when pursuing a policy
of maximal use of autologous tissue. The microporous
expanded polytetrafluoroethylene (PTFE) graft has been
used alternatively, but earlier reports on plain PTFE grafts
showed poor results. Further attempts at improving pa-
tency have included use of adjunctive procedures at distal
anastomosis and PTFE conduits that incorporated a thin
wall, an external support, or a tapered end. These changes,
along with other factors, are associated with better results,
but there has been renewed interest in cryopreserved allo-
grafts. A systematic review to appraise usage and combine
results of PFTE bypass grafting to infrapopliteal arteries
seemed opportune.
Surgical series are potential targets for meta-analysis,1
but variability among surgeons and patients at different
centers challenges validity. This interpretation may be too
restrictive when studies deal with a well-defined problem
and the severity of disease or use of poorly effective tech-
niques has an important role.2 Distal PTFE bypass grafting
is one such problem, because most studies of patients with
rest pain or tissue loss include few pedal bypass procedures
and describe less than optimal outcomes. Although sur-
geon skills may influence early results, the final outcome of
an initially patent PTFE graft cannot be considered sur-
geon-dependent. To understand the role of distal PTFE
grafts better, we conducted meta-analysis of published
studies of PTFE bypass grafting to infrapopliteal arteries to
assess midterm graft patency and foot salvage.
METHODS
Study identification. We read pertinent articles at
random to refine research questions and develop the initial
version of an instrument for data collection. To comply
with broad inclusiveness of studies,1 we made several mod-
ifications to the initial version before defining the final
protocol. Using the PubMed database and “PTFE” and
“bypass” as descriptors, we performed a search of articles
published from January 1980 through December 2001. As
a result, we examined the full text of more than 100 articles
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for possible inclusion and used the cited references to
identify additional studies. The senior author (M.A.), who
had participated in a similar meta-analysis,2 and two under-
graduate medical students (V.M.B., A.A.E.R.) conducted
the search. The authors were prepared to read articles
written in Spanish, French, Italian, and Portuguese, but no
useful article was found in a language other than English.
We prevented repeat inclusion of bypass procedures by
averting overlap of periods of patient inclusion in studies
from the same source, and used 43 studies to include 40
series in analysis of primary graft patency (PP),3-35 35 series
in analysis of secondary graft patency (SP),5-22,32-44 and 31
series in analysis of foot preservation (FP) (Appendix A,
online only).4,6,7,9-14,18-25,29,32-39,43,45 In an attempt to
retrieve missing data, we sent a letter to the authors of 22
single studies, but the response was disappointing.
Criteria for inclusion. Included articles satisfied the
following criteria: publication year from 1982 through
2001; series including at least 15 PTFE bypass grafts to an
infrapopliteal artery; use of survival analysis of any type;
units at risk for some intervals shown in survivor curves,
when life-tables were unavailable; use of PP or SP clearly
indicated; and follow-up of 2 or more years.
We violated the above criteria by accepting 7 series
with 8% to 29% bypasses to the below-knee popliteal
artery,19-21,35,42,43 8 series with 36% to 100% composite
PTFE-vein grafts in which the PTFE component did not
cross the knee joint,9,15,28,31,40,41,43,44 1 series with two
above-knee PTFE grafts,35 numbers at risk omitted in one
Kaplan-Meier curve,29 and uncertainty about type of pa-
tency or units at risk in 11 studies.12,15,17,34-37,39-41,44
Data extraction. The junior authors extracted the
data independently from standard life-tables (PP, n  18;
SP, n  12; FP, n  8), actuarial survivor curves (PP, n 
18; SP, n  19; FP, n  19), or Kaplan-Meier survivor
curves (PP, n 4; SP, n 4; FP, n 4). The senior author
checked all abstracted data to detect and resolve discor-
dance. When only survivor curves were available, we mea-
sured distance between convenient points in these curves to
both the time axis and the success axis to obtain survival
times and cumulated success rates, respectively. In 44 series
(PP, n 11; SP, n 15; FP, n 18), numbers of grafts or
feet at risk allowed for reliable reconstructed life tables.
These indicators were not supplied for all intervals in 17
series (PP, n  9; SP, n  6; FP, n  2) and were
completely lacking in 7 series (PP, n 2; SP, n 2; FP, n
3); consequently, the retrieved life table was less reliable.
For the sake of broad inclusiveness of studies, we often
inferred SP from PP data by using information available in
the text11,13,18,21,22,34,35 or assumed SP to be equivalent to
“cumulated patency rate.”36,40-42,44 In one study we re-
placed declared primary-assisted patency with SP.15 Occa-
sionally we inferred FP from survivor curves for PP or
SP.14,29,34,38 In two series we inferred PP from SP da-
ta.17,38 When life tables or survivor curves omitted out-
comes at 1 month, we looked for these data in the Results
section. Inasmuch as these outcomes were still missing for
26 series (PP, n  8; SP, n  9; FP, n  9), we restricted
analysis of these series to the second follow-up interval and
beyond.
Study quality. An ideal study should contain the rea-
sons for using PTFE grafts as well as the proportion of
patients requiring these grafts, life tables rather than
graphs, 1-month follow-up intervals, losses to follow-up,
and description of PP, SP, and FP. Also important are a
demographic profile linked to survival analysis, rates of
previous operation and tissue loss, regimen of postoperative
anticoagulant therapy, incidence of perigraft infection, and
data on further bypass grafting. We graded each of these
items 1 or 0 so that a perfect study would have a score of 14,
with a decrease of 1 point for each unmet requirement. The
main features of survival analysis and the measures of study
quality are presented in Appendix B (online only).
Selection of outcomes. Outcome measures of interest
were PP, SP, and FP. Qualification for PP required unin-
terrupted patency with no further intervention in the graft
or its anastomoses; SP after graft occlusion was achieved
when patency was restored and most of the original graft
and at least one anastomosis were retained in continuity.46
Since few studies reported the final level of amputation and
none reported survival times,3,11,15,17,29,35,38,40 this out-
come was reviewed only briefly.
Meta-analysis of subsets. We focused on the config-
uration of PTFE grafts and study quality in subgroup
meta-analysis. Pure PTFE grafts were described for PP in
13 series, for SP in 12 series, and for FP in 10 series. PTFE
grafts with distal adjuvant procedures were described for PP
in 27 series, for SP in 23 series, and for FP in 21 series.
Adjunctive procedures included composite PTFE-vein
grafts (PP, n  7; SP, n  8), patches (PP, n  6; SP, n 
4), cuffs (PP, n  4; SP, n  2), arteriovenous fistulas
(AVF) (PP, n  1, SP, n  2), or two or more of these
procedures combined (PP, n  9; SP, n  7). Of the
combination procedures, most (PP, n  7; SP, n  6)
combined AVF and another adjunctive procedure, and few
(PP, n  2; SP, n  1) combined adjunctive procedures
other than AVF. We analyzed all series describing PTFE
grafts with adjunctive procedures together, but also con-
sidered the influence of adjunctive procedures containing
AVF. For convenience, we used 7.5 as the cutoff to cate-
gorize scores for study quality. The demographic profile
and usual set of risk factors was unavailable for 29 series
(PP, n  13; SP, n  10; FP, n  6), limiting subgroup
meta-analysis and precluding meta-regression analysis.
With two exceptions,5,44 that information had been linked
to a wider group of infrainguinal grafts in these stud-
ies.3,8,18,22,25-28,34,37,41
Statistical methods. Initially for each series we calcu-
lated the success rate for each month of follow-up, and used
this rate as the treatment effect. In addition, for each series
we obtained within-series variance for each monthly success
rate, between-series variance for each month, and between-
interval variance (Appendix C, online only).47-49 These
variances were summed to weigh success rates and obtain a
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pooled measure of monthly success in a random-effects
meta-analysis, which assumes that included studies are a
random sample of the universe of studies. Finally, the
product of successive monthly pooled measures of treat-
ment effect allowed us to obtain pooled measures of cumu-
lative success and to calculate approximate confidence in-
tervals.
We investigated Weibull models that best fitted the
pooled survival curves. The Weibull model is a statistical
survivor function that uses two parameters to describe
survival along time. Compared with the Kaplan-Meier
product-limit method, the Weibull survival curve decreases
continuously, without steps and long flat tails, and better
captures continuity in nature.
Sensitivity analysis. Bias was introduced when the
included series contained either bypass grafts to the popli-
teal artery or composite PTFE-vein grafts with above-knee
PTFE segments only. To estimate such bias we calculated
the median of the appropriate relative risk for graft failure at
late follow-up from other studies.3,4,6,7,18-20,23-
29,36,37,41,50-52 For below-knee popliteal grafts, the median
was 0.78 for PP and 0.85 for SP, whereas for above-knee
popliteal grafts and composite grafts with an above-knee
PTFE only, the median was 0.65 for PP and 0.60 for SP.
A second source of bias was loss to follow-up, because
up to 60% of grafts lost within the first year may represent
failed grafts.53 We used data from six studies to calculate
averages for the proportion of lost units relative to censored
units.9,16,22,30,31,32 These averages were 22% for the first
month, 47% from 2 to 6 months, and 18% from 7 to 12
months. To mount a plausible scenario, we used 60% of the
grafts possibly lost within the first year of follow-up as
additional failures and a relative risk for failure of 0.75 for
below-knee popliteal grafts. For above-knee PTFE grafts
and composite grafts with the PTFE part above the knee
joint, our data would not tolerate a relative risk for primary
graft failure lower than 0.89; consequently, we used this
risk for PP, and 0.60 for both SP and FP.
Publication bias in meta-analysis of comparative studies
has been investigated with funnel-plot graphs. This tech-
nique plots study size against the treatment effect and
enables the meta-analyst to see, among studies of small size,
whether those describing higher results are in greater num-
ber than those describing lower results.54 Symmetric plots
around the pooled estimate indicates absence of publica-
tion bias. In this meta-analysis we plotted study size against
18-month outcomes in individual series.54
RESULTS
Pooled estimates for PP, SP, and FP and their corre-
sponding confidence intervals at some selected points in
follow-up are shown in Table I. Risk for secondary graft
failure exceeded risk for foot loss by a multiplication factor
of 1.36 to 1.72. In eight studies reviewed, thigh amputa-
tion accounted for 8% to 100% (median 49%) of foot losses.
Random-effects plots were nicely fitted by Weibull
models, and sensitivity analysis with these models showed
absolute decrease at 5-year follow-up of 2.9% for PP, 3.0%
for SP, and 4.9% for FP (Fig 1). Assumptions on loss to
follow-up were the main contributors to such decreases:
94% for PP, 97% for SP, and 96% for FP. When we consid-
ered fixed-effects modeling, absolute increase in the 5-year
estimate was 2.2% for PP, 1.7% for SP, and 4.4% for FP.
Subgroup meta-analyses showed higher pooled esti-
mates for PTFE grafts with adjunct procedures than for
PTFE grafts alone, but confidence regions overlapped (Ta-
ble II). Sensitivity analysis of this comparison decreased the
difference in 5-year estimates, from 5.0% to 3.4% for PP
(Fig 2), from 9.8% to 5.2% for SP, and from 2.6% to1.9%
for FP. Series of superior quality performed better for PP
and FP but not SP (Table II). Funnel plots symmetric
around averaged outcomes indicated that severe publica-
tion bias was unlikely (Appendix D, online only).
DISCUSSION
Uncontrolled series are naturally available from surgical
practice and do not pose complex ethical issues, but they
are a poor source of scientific evidence. Meta-analysis tar-
gets this weakness, and may expand the scientific impor-
tance of such series, although this possibility depends on
general acceptance of some standards. Of prime interest for
the particular case of distal PTFE grafts, all patients should
be followed up for at least 1 year; reporting of both PP and
SP should be mandatory; and an outcome measure com-
Table I. Pooled estimates of outcomes with random-effects meta-analysis
Follow-up
(mo)
Primary graft patency
(n  40)
Secondary graft patency
(n  35)
Foot preservation
(n  31)
1 83.9 (80.4, 87.5) 88.3 (84.9, 91.7) 93.2 (92.8, 93.6)
3 78.0 (73.5, 82.6) 82.3 (77.9, 86.8) 88.4 (84.6, 92.1)
6 69.9 (64.6, 75.2) 75.1 (69.6, 80.7) 83.2 (77.7, 88.7)
12 59.0 (53.3, 64.7) 66.4 (60.1, 72.7) 77.7 (71.7, 83.7)
18 53.9 (48.1, 59.6) 61.4 (55.1, 67.8) 74.1 (67.9, 80.3)
24 48.2 (42.3, 54.0) 56.5 (49.4, 63.6) 70.9 (64.5, 77.3)
36 40.8 (34.3, 47.4) 51.0 (43.2, 58.8) 66.2 (59.6, 72.8)
48 35.1 (27.8, 42.3) 45.5 (35.9, 55.1) 63.1 (55.1, 71.1)
60 30.5 (22.9, 38.2) 39.7 (28.9, 50.5) 55.7 (45.9, 65.5)
Values in parentheses represent 95% confidence interval.
n, Number of series combined.
JOURNAL OF VASCULAR SURGERY
Volume 37, Number 6 Albers et al 1265
bining patient survival, FP, and SP should be used. These
measures will reduce bias and better reflect patient experi-
ence. Second, standard life tables are preferred to survivor
curves and separate loss to follow-up from other mecha-
nisms of censoring. In addition to being imprecise and
prone to error, life tables reconstructed from survivor
curves cannot retrieve losses to follow-up. Third, first fol-
low-up at 1 month is an obvious need, and subsequent
follow-up intervals should be as short as possible and en-
compass all available data. This should prevail over the
recommendation of omitting estimates with SE greater
than 10%. Except for the latter, the preceding items have all
been recommended.46
Pooled patencies for distal PTFE grafts compared fa-
vorably with published estimates for allograft vessels. For
the 18-month follow-up, pooled PP of 53.9% was sur-
passed in one study with 26 venous allografts55 and another
study with 17 arterial allografts,56 but a set of nine allograft
series published in the last decade showed a dismal median
PP rate of 36%.55-63 Although illustrative, the foregoing
must be interpreted carefully. Indeed, allografts have been
used mainly as a last resort alternative, and secondary PTFE
grafts sometimes account for fewer than half the cas-
es.4,9,13,23,25,35,36,40 Several allograft series have also in-
cluded a greater proportion of either more favorable pop-
liteal bypass grafts or less favorable pedal bypass grafts.
Despite the importance of achieving acceptable graft
patency rates, FP is of utmost importance, mainly for
patients, and a 1-year FP rate as low as 45% may justify
infrainguinal bypass grafting in terms of walking ability and
quality of life.64 The present study was thus reassuring for
the use of distal PTFE grafts, because the lower limits of the
confidence intervals for pooled FP were greater than 45% in
the main meta-analysis (Table I) and the subgroup meta-
analyses (Table II). With properly selected patients with
critical ischemia at baseline, ischemic symptoms are likely to
reappear after graft failure, although this may be less valid if
the graft has functioned for a year or longer.14,31,34 This
idea is compatible with the pooled curves for FP being
nearer to the pooled curves for SP than to 100%. Clearly,
FP does not mean absence of critical ischemia, and the
differences between pooled estimates of FP and SP reflect
the joint effect of multiple PTFE grafts per limb, repeat
bypass procedures with other graft materials, and the inev-
itable inclusion of some patients at low risk for amputation.
Since the gap between SP and FP rates seems exaggerated,
SP rates may be more reliable, but this interpretation still
supports the merits of PTFE grafts.
For all three outcome measures, pooled estimates were
higher along follow-up for series of PTFE grafts with
adjunct procedures compared with series of plain PTFE
grafts; however, the overlap of confidence regions gave
poor statistical support to the corresponding differences.
Inconsistencies were found for the influence of study qual-
ity and use of AVF with regard to SP. In addition, the
difference of 1.2% between SP and PP within series of
PTFE grafts containing an adjuvant AVF can suggest that
AVFs were used in more adverse situations. On the con-
trary, the difference of 1.3% for FP would indicate similar
risks for AVFs and other adjuncts. Further studies are
necessary to determine the role of adjuncts in general.
Weibull models gave the best fit for all three outcomes
with surprisingly good precision. This capture of continuity
in nature may strengthen this meta-analysis in particular
and the meta-analysis of survival data in general. Weibull
models were also useful for sensitivity analysis and to show
this analysis graphically. Changes of less than 5% were
observed in the main meta-analysis, and the differences in
favor of PTFE grafts with adjuncts decreased in subgroup
meta-analysis. As strongly recommended approaches,1,54
sensitivity analysis and investigation of selective publication
indicated the robustness of our results and resistance to bias
from many sources.
This meta-analysis averted the inconvenience of esti-
mating event rates at a specific time by constructing more
informative pooled survivor curves. Which intervals to tar-
get in such meta-analysis depends on the research problem
and on the intervals used in the articles reviewed. Longer
intervals were used in meta-analysis of infrainguinal bypass
surgery,2 but early events after PTFE grafting are frequent
enough to justify monthly intervals here. To better account
for variability, we used random-effects modeling and con-
sequently obtained estimates that were slightly less optimis-
tic and approximately 50% less accurate. In contrast, other
authors have simply used numbers at risk to weigh survival
rates,65 but this approach omits variability of any sources
and does not represent a typical meta-analysis. More com-
plex Bayesian methods have been reported.66
At least two limitations must be recognized. First, this
was an observational study of other observational studies,
so the possibility of bias increases. Second, the recon-
structed life tables were but an approximation. However,
this meta-analysis outlined a strategy for dealing with sur-
vival data and provided solutions for some problems com-
monly encountered in the reviewed studies. It also con-
firmed that variability among series is an important issue to
Fig 1. Pooled survivor curves for primary graft patency (PP),
secondary graft patency (SP), and foot preservation (FP) (contin-
uous lines) closely match Weibull survivor curves (dotted lines with
circles). Sensitivity analysis at a plausible scenario (dotted lines with
squares) is also represented.
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consider, at least for earlier months of follow-up. In favor of
validity, distinctive features of the studies reviewed in-
cluded survival analysis of acceptable quality, high response
rates that increased the precision of estimates, use of similar
designs to answer some research questions, and existence of
a reference population to which the conclusions drawn can
be applied. Since graft material, degree of ischemia, and
level of distal anastomosis were restricted by design, the
effects of other possible confounders were judged tolerable.
In conclusion, meta-analysis revealed moderate success for
distal PTFE bypass grafts, but the usefulness of adjunctive
procedures at the distal anastomosis remains uncertain.
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